The stock's fall snapped a four-day winning streak.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Learn more about LLY stock here.

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Over the past month, Eli Lilly's stock rose by nearly 10%, a performance that aligns with the broader upward trend of the S&P 500 and Nasdaq, which have been bolstered by easing trade tensions and ...

Over the past month, shares of this drugmaker have returned +4.8%, compared to the Zacks S&P 500 composite's +7.2% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which ...

The S&P 500 pulled back from all‑time highs as oil jumped above $70, marking its largest weekly gain in years.

Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Shares of Eli Lilly have risen 1.7% so far this year against the industry ’s decline of 1.2%. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below.